Project Details
| Acronym | CN1-101 |
|---|---|
| Status | Active |
| Effective start/end date | 3/08/20 → 30/06/25 |
A phase I, open label, multi-center,dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Gurney, Howard (Associate Investigator)
- Sabanathan, Dhanusha (Associate Investigator)
Project: Research